• Savara flagged new analyses of molgramostim from its IMPALA and IMPALA-2 trials in autoimmune pulmonary alveolar proteinosis for presentation at CHEST 2026.
• Long-term IMPALA-2 open-label data will be presented in the future, focusing on sustained efficacy and safety in treated patients.
• An IMPALA analysis will also be presented, highlighting treatment effects in patients with milder disease-related diffusion impairment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261012229402) on October 12, 2026, and is solely responsible for the information contained therein.